25 October 2019
Renewed promise for early Alzheimer’s drug signals potential for Cambridge Cognition’s assessment so
Following a consultation with the U.S. Food and Drug Administration (FDA), Biogen and Eisai have announced plans to pursue regulatory approval for aducanumab, which would be the first therapy to tackle clinical decline in early Alzheimer's disease. If successful, this presents an opportunity for Cambridge Cognition whose CANTABTM assessments are specifically sensitive to the early cognitive decline during Alzheimer's disease.
14 August 2019
Cambridge Cognition Holdings is deeply saddened to report the death of Nick Kerton, the Company’s former Chief Executive Officer and Non-executive Director, after a long fight with cancer.
12 August 2019
Cambridge Cognition is pleased to announce its expansion into the Chinese market with the Company’s Cambridge Neuropsychological Test Automated Battery (“CANTAB”) computerised assessments. This move strengthens the Company’s global position, having announced a major opportunity in India earlier this year.
19 July 2019
Cambridge Cognition is pleased to announce the second commercial partnership with a leading pharmaceutical company, for its NeuroVocalixTM platform. NeuroVocalixTM is a unique voice biomarker technology and the product was launched last year and recently presented ground-breaking demonstrable evidence of the potential at a major global Alzheimer’s conference.
1 July 2019
Cambridge Cognition today announced the appointment of Debra Leeves as a Non-Executive Director with immediate effect.
24 May 2019
We’re pleased to announce that NHS Bedfordshire Clinical Commissioning Group (CCG) is introducing our iPad-based memory assessment tool into 50 general practices.